Search

Your search keyword '"Brunner-La Rocca, Hans Peter"' showing total 1,070 results
Start Over Author "Brunner-La Rocca, Hans Peter"
1,070 results on '"Brunner-La Rocca, Hans Peter"'

10. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial

Author

Emans, M E, Beeres, S L M A, Heerebeek, L, Kirchhof, C, Van Ramshorst, J, Spee, R, Smilde, T, Van Eck, M, Kaplan, E, Hazeleger, R, Tukkie, R, Feenema, M, Kok, W, Van Halm, V, Handoko, M L, Van Kimmenade, R, Post, M, Van Mieghem, N, Manintveld, O C, Brugts, Jasper J, Radhoe, Sumant P, Clephas, Pascal R D, Aydin, Dilan, van Gent, Marco W F, Szymanski, Mariusz K, Rienstra, Michiel, van den Heuvel, Mieke H, da Fonseca, Carlos A, Linssen, Gerard C M, Borleffs, C Jan Willem, Boersma, Eric, Asselbergs, Folkert W, Mosterd, Arend, Brunner-La Rocca, Hans-Peter, and de Boer, Rudolf A

Published
2023
Full Text
View/download PDF

14. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial

Author

Verdonschot, Job A.J., Ferreira, JoÃo Pedro, Pizard, Anne, Pellicori, Pierpaolo, Brunner La Rocca, Hans-Peter, Clark, Andrew L., Cosmi, Franco, Cuthbert, Joe, Girerd, Nicolas, Waring, Olivia J., Henkens, Michiel H.T.M., Mariottoni, Beatrice, Petutschnigg, Johannes, Rossignol, Patrick, Hazebroek, Mark R., Cleland, John G.F., Zannad, Faiez, and Heymans, Stephane R.B.

Published
2022
Full Text
View/download PDF

15. Patients' expectations and experiences with the usage of a self-care application for heart failure: A qualitative interview study.

Author

Neumann, Anne, Steiner, Bianca, Verket, Marlo, Kanna, Niveditha Daneeza Dinesh, Hill, Loreena, McNulty, Anne, Boyne, Josiane J. J., Murphy, Marguerite, Maaser, Yannick, Fitzsimons, Donna, Barrett, Matthew, Ski, Chantal F., Schütt, Katharina, Helms, Thomas M., Brunner-La Rocca, Hans-Peter, and Zippel-Schultz, Bettina

Published
2024
Full Text
View/download PDF

18. Health burden in type 2 diabetes and prediabetes in The Maastricht Study

Author

Veugen, Marja G. J., Onete, Veronica G., Henry, Ronald M. A., Brunner-La Rocca, Hans-Peter, Koster, Annemarie, Dagnelie, Pieter C., Schaper, Nicolaas C., Sep, Simone J. S., van der Kallen, Carla J. H., van Boxtel, Martin P. J., Reesink, Koen D., Schouten, Johannes S., Savelberg, Hans H. C. M., Köhler, Sebastian, Verhey, Frans R., van den Bergh, Joop P. W., Schram, Miranda T., and Stehouwer, Coen D. A.

Published
2022
Full Text
View/download PDF

19. Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study

Author

Malgie, Jishnu, primary, Wilde, Mariëlle I., additional, Clephas, Pascal R.D., additional, Emans, Mireille E., additional, Koudstaal, Stefan, additional, Schaap, Jeroen, additional, Mosterd, Arend, additional, van Ramshorst, Jan, additional, Wardeh, Alexander J., additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, Wierda, Eric, additional, Borleffs, C. Jan Willem, additional, Saraber, Colette, additional, Beeres, Saskia L.M.A., additional, van Kimmenade, Roland, additional, Jansen Klomp, Wouter, additional, Denham, Robert, additional, da Fonseca, Carlos A., additional, Klip, IJsbrand T., additional, Manintveld, Olivier C., additional, van der Boon, Robert M.A., additional, van Ofwegen, Clara E.E., additional, Yilmaz, Ayten, additional, Pisters, Ron, additional, Linssen, Gerard C.M., additional, Faber, Nikola, additional, van Heerebeek, Loek, additional, van de Swaluw, Julio E.C., additional, Bouhuijzen, Lex J., additional, Post, Marco C., additional, Kuijper, Aaf F.M., additional, Wu, Ka wai, additional, van Beek, Eugène A., additional, Hesselink, Tim, additional, Kleijn, Lennaert, additional, Kurvers, Maurice J.M., additional, Tio, René A., additional, Langerveld, Jorina, additional, van Dalen, Bas M., additional, van Eck, J.W. Martijn, additional, Handoko, M. Louis, additional, Hermans, Walter R.M., additional, Koornstra‐Wortel, Hetty J.J., additional, Szymanski, Mariusz K., additional, Rooker, Dennis, additional, Tandjung, Kenneth, additional, Eijsbouts, Sabine C.M., additional, Asselbergs, Folkert W., additional, van der Meer, Peter, additional, Brunner‐La Rocca, Hans‐Peter, additional, de Boer, Rudolf A., additional, and Brugts, Jasper J., additional

Published
2024
Full Text
View/download PDF

20. NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories

Author

Vergaro, Giuseppe, Gentile, Francesco, Meems, Laura M.G., Aimo, Alberto, Januzzi, James L., Jr., Richards, A. Mark, Lam, Carolyn S.P., Latini, Roberto, Staszewsky, Lidia, Anand, Inder S., Cohn, Jay N., Ueland, Thor, Gullestad, Lars, Aukrust, Pål, Brunner-La Rocca, Hans-Peter, Bayes-Genis, Antoni, Lupón, Josep, Yoshihisa, Akiomi, Takeishi, Yasuchika, Egstrup, Michael, Gustafsson, Ida, Gaggin, Hanna K., Eggers, Kai M., Huber, Kurt, Gamble, Greg D., Ling, Lieng H., Leong, Kui Tong Gerard, Yeo, Poh Shuah Daniel, Ong, Hean Yee, Jaufeerally, Fazlur, Ng, Tze P., Troughton, Richard, Doughty, Robert N., Devlin, Gerry, Lund, Mayanna, Giannoni, Alberto, Passino, Claudio, de Boer, Rudolf A., and Emdin, Michele

Published
2021
Full Text
View/download PDF

21. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Author

Harjola, Veli-Pekka, Mullens, Wilfried, Banaszewski, Marek, Bauersachs, Johann, Brunner-La Rocca, Hans-Peter, Chioncel, Ovidiu, Collins, Sean, Doehner, Wolfram, Filippatos, Gerasimos, Flammer, Andreas, Fuhrmann, Valentin, Lainscak, Mitja, Lassus, Johan, Legrand, Matthieu, Masip, Josep, Mueller, Christian, Papp, Zoltán, Parissis, John, Platz, Elke, Rudiger, Alain, Ruschitzka, Frank, Schäfer, Andreas, Seferovic, Petar, Skouri, Hadi, Yilmaz, Mehmet, and Mebazaa, Alexandre

Subjects
Heart failure, Multiple organ failure, Venous congestion, Acute Disease, Cardiology, Diagnostic Imaging, Disease Management, Europe, Heart Failure, Humans, Multiple Organ Failure, Societies, Medical
Abstract

Organ injury and impairment are commonly observed in patients with acute heart failure (AHF), and congestion is an essential pathophysiological mechanism of impaired organ function. Congestion is the predominant clinical profile in most patients with AHF; a smaller proportion presents with peripheral hypoperfusion or cardiogenic shock. Hypoperfusion further deteriorates organ function. The injury and dysfunction of target organs (i.e. heart, lungs, kidneys, liver, intestine, brain) in the setting of AHF are associated with increased risk for mortality. Improvement in organ function after decongestive therapies has been associated with a lower risk for post-discharge mortality. Thus, the prevention and correction of organ dysfunction represent a therapeutic target of interest in AHF and should be evaluated in clinical trials. Treatment strategies that specifically prevent, reduce or reverse organ dysfunction remain to be identified and evaluated to determine if such interventions impact mortality, morbidity and patient-centred outcomes. This paper reflects current understanding among experts of the presentation and management of organ impairment in AHF and suggests priorities for future research to advance the field.

Published
2017

23. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

Author

Ferreira, João Pedro, Verdonschot, Job, Wang, Ping, Pizard, Anne, Collier, Timothy, Ahmed, Fozia Z., Brunner-La-Rocca, Hans-Peter, Clark, Andrew L., Cosmi, Franco, Cuthbert, Joe, Díez, Javier, Edelmann, Frank, Girerd, Nicolas, González, Arantxa, Grojean, Stéphanie, Hazebroek, Mark, Khan, Javed, Latini, Roberto, Mamas, Mamas A., Mariottoni, Beatrice, Mujaj, Blerim, Pellicori, Pierpaolo, Petutschnigg, Johannes, Pieske, Burkert, Rossignol, Patrick, Rouet, Philippe, Staessen, Jan A., Cleland, John G.F., Heymans, Stephane, and Zannad, Faiez

Published
2021
Full Text
View/download PDF

24. Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment

Author

Amier, Raquel P., Marcks, Nick, Hooghiemstra, Astrid M., Nijveldt, Robin, van Buchem, Mark A., de Roos, Albert, Biessels, Geert Jan, Kappelle, L. Jaap, van Oostenbrugge, Robert J., van der Geest, Rob J., Bots, Michiel L., Greving, Jacoba P., Niessen, Wiro J., van Osch, Matthias J.P., de Bresser, Jeroen, van de Ven, Peter M., van der Flier, Wiesje M., Brunner-La Rocca, Hans-Peter, and van Rossum, Albert C.

Published
2021
Full Text
View/download PDF

25. Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO‐HF).

Author

Patwala, Ashish, Barker, Diane, Da Costa, Antoine, Bayard, Geoffrey, Brunner‐La Rocca, Hans‐Peter, Fontes‐Carvalho, Ricardo, De la Fuente, Luis, Goralski, Marc, Mahon, Niall G., Roque, David, Santos, Mario, Yousef, Zaheer, Ben Hamouda, Hela, Teal, Mark, Christory, François, Ahmed, Fozia Zahir, and Mebazaa, Alexandre

Subjects
HEART failure patients, MEDICAL personnel, PATIENT monitoring, HEART failure, INPATIENT care
Abstract

Aims: Many European healthcare providers struggle to adopt multidisciplinary, integrated care pathways for people with heart failure (HF) as recommended by the European Society of Cardiology. PRO‐HF (Program to Optimize Heart Failure Patient Pathways) was developed to help clinicians identify strengths, gaps, and shortcomings in their HF pathways and support tailored interventions to optimize pathways and enhance patient care. We report initial findings from baseline assessments of HF pathway characteristics and challenges from 10 hospitals in six European countries (France, Ireland, Portugal, Spain, The Netherlands, and United Kingdom). Methods and results: Baseline assessments were holistic appraisals of full HF services to calibrate current status and development needs and assist management teams in prioritizing improvement projects. Assessments were performed using a comprehensive checklist of measures covering the HF patient journey from diagnosis to ongoing follow‐up. These included a digital survey sent to full HF care teams and one‐to‐one interviews. The digital survey focused on four key areas (HF outpatient clinic; remote patient management; efficient device implantation and inpatient pathways; and network maximization) and 16 dimensions of excellence. Priority areas and themes for action identified in baseline assessments were (i) provision of HF specialist care; (ii) data capture and analysis; (iii) institutional care protocols; (iv) hospital‐wide strategies; and (v) multidisciplinary teams (MDTs). Suboptimal specialist care of emergency inpatients was an issue at all hospitals and prioritized at 8/10. Availability and accessibility of data on patients, activities, and outcomes was an issue at all hospitals and prioritized by 4/10. A lack of clear protocols, templates, and tools for some HF activities created variability in patient care (e.g., HF specialist consultations, diagnostic testing, follow‐up appointments, medications, and device eligibility) and inefficient use of clinician time. This made it difficult to initiate new technologies (e.g., remote patient monitoring) due to the risk of overburdening staff. MDTs were frequently understaffed. Multiple interventions were identified to address gaps and shortcomings that could be tailored to specific needs of individual hospitals (e.g., inpatient pathway optimization, creation/optimization of HF outpatient clinics, development of an HF performance dashboard, enhancement of protocol adherence, streamlining cardiac resynchronisation therapy pathways, and MDT coordination). Conclusions: PRO‐HF provides a valuable opportunity to identify gaps and significant shortcomings in HF pathways in European hospitals. Preliminary findings from hospitals that have initiated suggested changes to address these challenges are encouraging, though longer‐term follow‐up from more hospitals is needed to confirm the impact of PRO‐HF on HF pathway optimization and patient care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study.

Author

Allach, Youssra, Barry‐Loncq de Jong, Mylene, Clephas, Pascal R.D., van Gent, Marco W.F., Brunner‐La Rocca, Hans‐Peter, Szymanski, Mariusz K., van Halm, Vokko P., Handoko, M. Louis, Kok, Wouter E.M., Asselbergs, Folkert W., van Kimmenade, Roland R.J., Manintveld, Olivier C., van Mieghem, Nicolas M.D.A., Beeres, Saskia L.M.A., Rienstra, Michiel, Post, Marco C., van Heerebeek, Loek, Borleffs, C. Jan Willem, Tukkie, Raymond, and Mosterd, Arend

Subjects
PULMONARY artery, HEART failure, HEART failure patients, CARDIOVASCULAR disease related mortality, DESIGN failures, PROGNOSIS
Abstract

Aims: Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF‐related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early‐stage intervention, since haemodynamic congestion precedes clinical symptoms. Methods: The BioMEMS study, a substudy of the MONITOR‐HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR‐HF trial were collected at baseline, 3‐, 6‐, and 12‐month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS‐HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death. Conclusion: Since the prognostic value of single baseline measurements of biomarkers like N‐terminal pro‐B‐type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Bartunek, Jozef, Bondue, Antoine, Van Craenenbroeck, Emeline, Kubanek, Milos, Zemanek, David, Jensen, Morten, Mogensen, Jens, Thune, Jens Jakob, Charron, Philippe, Hagege, Albert, Lairez, Olivier, Trochu, Jean-Noël, Axthelm, Christoph, Duengen, Hans-Dirk, Frey, Norbert, Mitrovic, Veselin, Preusch, Michael, Schulz-Menger, Jeanette, Seidler, Tim, Arad, Michael, Halabi, Majdi, Katz, Amos, Monakier, Daniel, Paz, Offir, Viskin, Samuel, Zwas, Donna, Olivotto, Iacopo, Brunner-La Rocca, Hans Peter, Michels, Michelle, Dudek, Dariusz, Oko-Sarnowska, Zofia, Oreziak, Artur, Wojakowski, Wojciech, Cardim, Nuno, Pereira, Helder, Barriales-Villa, Roberto, García Pavia, Pablo, Gimeno Blanes, Juan, Hidalgo Urbano, Rafael, Rincón Diaz, Luis Miguel, Elliott, Perry, Yousef, Zaheer, Abraham, Theodore, Afshar, Kia, Alvarez, Paulino, Bach, Richard, Becker, Richard, Choudhury, Lubna, Fermin, David, Jacoby, Daniel, Jefferies, John, Kramer, Christopher, Lakdawala, Neal, Lester, Steven, Marian, Ali, Masri, Ahmad, Maurer, Mathew, Nagueh, Sherif, Owens, Anjali, Owens, David, Rader, Florian, Saberi, Sara, Sherrid, Mark, Shirani, Jamshid, Symanski, John, Turer, Aslan, Wang, Andrew, Wever-Pinzon, Omar, Wheeler, Matthew, Wong, Timothy, Yamani, Mohamad, Abraham, Theodore P, Garcia-Pavia, Pablo, Lakdawala, Neal K, Wheeler, Matthew T, Jensen, Morten K, Gimeno-Blanes, Juan, Myers, Jonathan, Hegde, Sheila M, Solomon, Scott D, Sehnert, Amy J, Zhang, David, Li, Wanying, Bhattacharya, Mondira, Edelberg, Jay M, Waldman, Cynthia Burstein, Lester, Steven J, and Ho, Carolyn Y

Published
2020
Full Text
View/download PDF

30. Value of Speckle Tracking–Based Deformation Analysis in Screening Relatives of Patients With Asymptomatic Dilated Cardiomyopathy

Author

Verdonschot, Job A.J., Merken, Jort J., Brunner-La Rocca, Hans-Peter, Hazebroek, Mark R., Eurlings, Casper G.M.J., Thijssen, Eline, Wang, Ping, Weerts, Jerremy, van Empel, Vanessa, Schummers, Georg, Schreckenberg, Marcus, van den Wijngaard, Arthur, Lumens, Joost, Brunner, Han G., Heymans, Stephane R.B., Krapels, Ingrid P.C., and Knackstedt, Christian

Published
2020
Full Text
View/download PDF

31. Cytotoxic T Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy.

Author

Sikking, Maurits A., Harding, Daniel, Henkens, Michiel T.H.M., Stroeks, Sophie L.V.M., Venner, Max F.G.H.M., Nihant, Bastien, van Leeuwen, Rick E.W., Fanti, Silvia, Li, Xiaofei, van Paassen, Pieter, Knackstedt, Christian, Brunner-la Rocca, Hans-Peter, van Empel, Vanessa P.M., Verdonschot, Job A.J., Marelli-Berg, Federica M., and Heymans, Stephane R.B.

Published
2024
Full Text
View/download PDF

32. Orthostatic hypotension, cognition and structural brain imaging in hemodynamically impaired patients

Author

Projectafdeling CVZ, Neurologen, Brain, Circulatory Health, Starmans, Naomi L.P., Wolters, Frank J., Leeuwis, Anna E., Bron, Esther E., de Bresser, Jeroen, Brunner-La Rocca, Hans Peter, Staals, Julie, Muller, Majon, Biessels, Geert Jan, Kappelle, L. Jaap, on behalf of the Heart-Brain Connection Consortium, Projectafdeling CVZ, Neurologen, Brain, Circulatory Health, Starmans, Naomi L.P., Wolters, Frank J., Leeuwis, Anna E., Bron, Esther E., de Bresser, Jeroen, Brunner-La Rocca, Hans Peter, Staals, Julie, Muller, Majon, Biessels, Geert Jan, Kappelle, L. Jaap, and on behalf of the Heart-Brain Connection Consortium

Published
2024

33. Alzheimer's Disease and Cognitive Decline in Patients with Cardiovascular Diseases Along the Heart-Brain Axis

Author

Neurologen, Brain, Circulatory Health, Trieu, Calvin, van Harten, Argonde C., Leeuwis, Anna E., Exalto, Lieza G., Hooghiemstra, Astrid M., Verberk, Inge M.W., Allaart, Cor P., Brunner-La Rocca, Hans Peter, Kappelle, L. Jaap, van Oostenbrugge, Robert J., Biessels, Geert Jan, Teunissen, Charlotte E., van der Flier, Wiesje M., Heart-Brain Connection Consortium, Neurologen, Brain, Circulatory Health, Trieu, Calvin, van Harten, Argonde C., Leeuwis, Anna E., Exalto, Lieza G., Hooghiemstra, Astrid M., Verberk, Inge M.W., Allaart, Cor P., Brunner-La Rocca, Hans Peter, Kappelle, L. Jaap, van Oostenbrugge, Robert J., Biessels, Geert Jan, Teunissen, Charlotte E., van der Flier, Wiesje M., and Heart-Brain Connection Consortium

Published
2024

34. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study

Author

Team Medisch, Circulatory Health, Malgie, Jishnu, Wilde, Mariëlle I, Clephas, Pascal R D, Emans, Mireille E, Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J, van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C Jan Willem, Saraber, Colette, Beeres, Saskia L M A, van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A, Klip, IJsbrand T, Manintveld, Olivier C, van der Boon, Robert M A, van Ofwegen, Clara E E, Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C M, Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E C, Bouhuijzen, Lex J, Post, Marco C, Kuijper, Aaf F M, Wu, Ka Wai, van Beek, Eugène A, Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J M, Tio, René A, Langerveld, Jorina, van Dalen, Bas M, van Eck, J W Martijn, Handoko, M Louis, Hermans, Walter R M, Koornstra-Wortel, Hetty J J, Szymanski, Mariusz K, Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C M, Asselbergs, Folkert W, van der Meer, Peter, Brunner-La Rocca, Hans-Peter, de Boer, Rudolf A, Brugts, Jasper J, Team Medisch, Circulatory Health, Malgie, Jishnu, Wilde, Mariëlle I, Clephas, Pascal R D, Emans, Mireille E, Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J, van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C Jan Willem, Saraber, Colette, Beeres, Saskia L M A, van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A, Klip, IJsbrand T, Manintveld, Olivier C, van der Boon, Robert M A, van Ofwegen, Clara E E, Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C M, Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E C, Bouhuijzen, Lex J, Post, Marco C, Kuijper, Aaf F M, Wu, Ka Wai, van Beek, Eugène A, Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J M, Tio, René A, Langerveld, Jorina, van Dalen, Bas M, van Eck, J W Martijn, Handoko, M Louis, Hermans, Walter R M, Koornstra-Wortel, Hetty J J, Szymanski, Mariusz K, Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C M, Asselbergs, Folkert W, van der Meer, Peter, Brunner-La Rocca, Hans-Peter, de Boer, Rudolf A, and Brugts, Jasper J

Published
2024

35. Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure:Design and rationale of the BioMEMS study

Author

Allach, Youssra, de Jong, Mylene Barry-Loncq, Clephas, Pascal R. D., van Gent, Marco W. F., Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K., van Halm, Vokko P., Handoko, M. Louis, Kok, Wouter E. M., Asselbergs, Folkert W., van Kimmenade, Roland R. J., Manintveld, Olivier C., van Mieghem, Nicolas M. D. A., Beeres, Saskia L. M. A., Rienstra, Michiel, Post, Marco C., van Heerebeek, Loek, Borleffs, C. Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C. M., Spee, Ruud F., Emans, Mireille E., Smilde, Tom D. J., van Ramshorst, Jan, Kirchhof, Charles J. H. J., Feenema-Aardema, Margriet W., da Fonseca, Carlos A., van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J. W. Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A., Brugts, Jasper J., Allach, Youssra, de Jong, Mylene Barry-Loncq, Clephas, Pascal R. D., van Gent, Marco W. F., Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K., van Halm, Vokko P., Handoko, M. Louis, Kok, Wouter E. M., Asselbergs, Folkert W., van Kimmenade, Roland R. J., Manintveld, Olivier C., van Mieghem, Nicolas M. D. A., Beeres, Saskia L. M. A., Rienstra, Michiel, Post, Marco C., van Heerebeek, Loek, Borleffs, C. Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C. M., Spee, Ruud F., Emans, Mireille E., Smilde, Tom D. J., van Ramshorst, Jan, Kirchhof, Charles J. H. J., Feenema-Aardema, Margriet W., da Fonseca, Carlos A., van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J. W. Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A., and Brugts, Jasper J.

Abstract

Aims: Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF-related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early-stage intervention, since haemodynamic congestion precedes clinical symptoms. Methods: The BioMEMS study, a substudy of the MONITOR-HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR-HF trial were collected at baseline, 3-, 6-, and 12-month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS-HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death. Conclusion: Since the prognostic value of single baseline measurements of biomarkers like N-terminal pro-B-type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively.

Published
2024

36. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients:First data from the TITRATE-HF study

Author

Malgie, Jishnu, Wilde, Mariëlle I., Clephas, Pascal R.D., Emans, Mireille E., Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J., van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C. Jan Willem, Saraber, Colette, Beeres, Saskia L.M.A., van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A., Klip, IJsbrand T., Manintveld, Olivier C., van der Boon, Robert M.A., van Ofwegen, Clara E.E., Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C.M., Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E.C., Bouhuijzen, Lex J., Post, Marco C., Kuijper, Aaf F.M., Wu, Ka wai, van Beek, Eugène A., Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J.M., Tio, René A., Langerveld, Jorina, van Dalen, Bas M., van Eck, J. W.Martijn, Handoko, M. Louis, Hermans, Walter R.M., Koornstra-Wortel, Hetty J.J., Szymanski, Mariusz K., Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C.M., Asselbergs, Folkert W., van der Meer, Peter, Brunner-La Rocca, Hans Peter, de Boer, Rudolf A., Brugts, Jasper J., Malgie, Jishnu, Wilde, Mariëlle I., Clephas, Pascal R.D., Emans, Mireille E., Koudstaal, Stefan, Schaap, Jeroen, Mosterd, Arend, van Ramshorst, Jan, Wardeh, Alexander J., van Wijk, Sandra, van den Heuvel, Mieke, Wierda, Eric, Borleffs, C. Jan Willem, Saraber, Colette, Beeres, Saskia L.M.A., van Kimmenade, Roland, Jansen Klomp, Wouter, Denham, Robert, da Fonseca, Carlos A., Klip, IJsbrand T., Manintveld, Olivier C., van der Boon, Robert M.A., van Ofwegen, Clara E.E., Yilmaz, Ayten, Pisters, Ron, Linssen, Gerard C.M., Faber, Nikola, van Heerebeek, Loek, van de Swaluw, Julio E.C., Bouhuijzen, Lex J., Post, Marco C., Kuijper, Aaf F.M., Wu, Ka wai, van Beek, Eugène A., Hesselink, Tim, Kleijn, Lennaert, Kurvers, Maurice J.M., Tio, René A., Langerveld, Jorina, van Dalen, Bas M., van Eck, J. W.Martijn, Handoko, M. Louis, Hermans, Walter R.M., Koornstra-Wortel, Hetty J.J., Szymanski, Mariusz K., Rooker, Dennis, Tandjung, Kenneth, Eijsbouts, Sabine C.M., Asselbergs, Folkert W., van der Meer, Peter, Brunner-La Rocca, Hans Peter, de Boer, Rudolf A., and Brugts, Jasper J.

Abstract

Aims: Despite clear guideline recommendations for initiating four drug classes in all patients with heart failure (HF) with reduced ejection fraction (HFrEF) and the availability of rapid titration schemes, information on real-world implementation lags behind. Closely following the 2021 ESC HF guidelines and 2023 focused update, the TITRATE-HF study started to prospectively investigate the use, sequencing, and titration of guideline-directed medical therapy (GDMT) in HF patients, including the identification of implementation barriers. Methods and results: TITRATE-HF is an ongoing long-term HF registry conducted in the Netherlands. Overall, 4288 patients from 48 hospitals were included. Among these patients, 1732 presented with de novo, 2240 with chronic, and 316 with worsening HF. The median age was 71 years (interquartile range [IQR] 63–78), 29% were female, and median ejection fraction was 35% (IQR 25–40). In total, 44% of chronic and worsening HFrEF patients were prescribed quadruple therapy. However, only 1% of HFrEF patients achieved target dose for all drug classes. In addition, quadruple therapy was more often prescribed to patients treated in a dedicated HF outpatient clinic as compared to a general cardiology outpatient clinic. In each GDMT drug class, 19% to 36% of non-use in HFrEF patients was related to side-effects, intolerances, or contraindications. In the de novo HF cohort, 49% of patients already used one or more GDMT drug classes for other indications than HF. Conclusion: This first analysis of the TITRATE-HF study reports relatively high use of GDMT in a contemporary HF cohort, while still showing room for improvement regarding quadruple therapy. Importantly, the use and dose of GDMT were suboptimal, with the reasons often remaining unclear. This underscores the urgency for further optimization of GDMT and implementation strategies within HF management.

Published
2024

37. Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study

Author

Team Medisch, Circulatory Health, Allach, Youssra, Barry-Loncq de Jong, Mylene, Clephas, Pascal R D, van Gent, Marco W F, Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K, van Halm, Vokko P, Handoko, M Louis, Kok, Wouter E M, Asselbergs, Folkert W, van Kimmenade, Roland R J, Manintveld, Olivier C, van Mieghem, Nicolas M D A, Beeres, Saskia L M A, Rienstra, Michiel, Post, Marco C, van Heerebeek, Loek, Borleffs, C Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C M, Spee, Ruud F, Emans, Mireille E, Smilde, Tom D J, van Ramshorst, Jan, Kirchhof, Charles J H J, Feenema-Aardema, Margriet W, da Fonseca, Carlos A, van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J W Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A, Brugts, Jasper J, Team Medisch, Circulatory Health, Allach, Youssra, Barry-Loncq de Jong, Mylene, Clephas, Pascal R D, van Gent, Marco W F, Brunner-La Rocca, Hans-Peter, Szymanski, Mariusz K, van Halm, Vokko P, Handoko, M Louis, Kok, Wouter E M, Asselbergs, Folkert W, van Kimmenade, Roland R J, Manintveld, Olivier C, van Mieghem, Nicolas M D A, Beeres, Saskia L M A, Rienstra, Michiel, Post, Marco C, van Heerebeek, Loek, Borleffs, C Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C M, Spee, Ruud F, Emans, Mireille E, Smilde, Tom D J, van Ramshorst, Jan, Kirchhof, Charles J H J, Feenema-Aardema, Margriet W, da Fonseca, Carlos A, van den Heuvel, Mieke, Hazeleger, Ronald, van Eck, J W Martijn, Boersma, Eric, Kardys, Isabella, de Boer, Rudolf A, and Brugts, Jasper J

Published
2024

38. Guideline implementation, drug sequencing, and quality of care in heart failure:design and rationale of TITRATE-HF

Author

Clephas, Pascal R.D., Malgie, Jishnu, Schaap, Jeroen, Koudstaal, Stefan, Emans, Mireille, Linssen, Gerard C.M., de Boer, Grytsje A., van Heerebeek, Loek, Borleffs, C. Jan Willem, Manintveld, Olivier C., van Empel, Vanessa, van Wijk, Sandra, van den Heuvel, Mieke, da Fonseca, Carlos, Damman, Kevin, van Ramshorst, Jan, van Kimmenade, Roland, van de Ven, Arjen R.T., Tio, René A., van Veghel, Dennis, Asselbergs, Folkert W., de Boer, Rudolf A., van der Meer, Peter, Greene, Stephen J., Brunner-La Rocca, Hans Peter, Brugts, Jasper J., Clephas, Pascal R.D., Malgie, Jishnu, Schaap, Jeroen, Koudstaal, Stefan, Emans, Mireille, Linssen, Gerard C.M., de Boer, Grytsje A., van Heerebeek, Loek, Borleffs, C. Jan Willem, Manintveld, Olivier C., van Empel, Vanessa, van Wijk, Sandra, van den Heuvel, Mieke, da Fonseca, Carlos, Damman, Kevin, van Ramshorst, Jan, van Kimmenade, Roland, van de Ven, Arjen R.T., Tio, René A., van Veghel, Dennis, Asselbergs, Folkert W., de Boer, Rudolf A., van der Meer, Peter, Greene, Stephen J., Brunner-La Rocca, Hans Peter, and Brugts, Jasper J.

Abstract

Aims: Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF with reduced ejection fraction (HFrEF). A clear challenge exists to adequately implement guideline-directed medical therapy (GDMT) regarding the sequencing of drugs and timely reaching target dose. It is largely unknown how the paradigm shift from a serial and sequential approach for drug therapy to early parallel application of the four drug classes will be executed in daily clinical practice, as well as the reason clinicians may not adhere to new guidelines. We present the design and rationale for the real-world TITRATE-HF study, which aims to assess sequencing strategies for GDMT initiation, dose titration patterns (order and speed), intolerance for GDMT, barriers for implementation, and long-term outcomes in patients with de novo, chronic, and worsening HF. Methods and results: A total of 4000 patients with HFrEF, HF with mildly reduced ejection fraction, and HF with improved ejection fraction will be enrolled in >40 Dutch centres with a follow-up of at least 3 years. Data collection will include demographics, physical examination and vital parameters, electrocardiogram, laboratory measurements, echocardiogram, medication, and quality of life. Detailed information on titration steps will be collected for the four GDMT drug classes. Information will include date, primary reason for change, and potential intolerances. The primary clinical endpoints are HF-related hospitalizations, HF-related urgent visits with a need for intravenous diuretics, all-cause mortality, and cardiovascular mortality. Conclusions: TITRATE-HF is a real-world multicentre longitudinal registry that will provide unique information on contemporary GDMT implementation, sequencing strategies (order and speed), and prognosis in de novo, worsening, and chronic HF patients.

Published
2024

41. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.

Author

Kobayashi, Masatake, Ferreira, João Pedro, Duarte, Kevin, Bresso, Emmanuel, Huttin, Olivier, Bozec, Erwan, Brunner La Rocca, Hans‐Peter, Delles, Christian, Clark, Andrew L., Edelmann, Frank, González, Arantxa, Heymans, Stephane, Pellicori, Pierpaolo, Petutschnigg, Johannes, Verdonschot, Job A.J., Rossignol, Patrick, Cleland, John G.F., Zannad, Faiez, and Girerd, Nicolas

Subjects
BRAIN natriuretic factor, LEFT heart atrium, SOMATOMEDIN, PROTEOMICS, SPIRONOLACTONE
Abstract

Aims: High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characteristics associated with left atrial volume indexed by body surface area (LAVi), and whether LAVi influences the response to spironolactone on biomarker expression and clinical variables. Methods and results: In the HOMAGE trial, where people at risk of heart failure were randomized to spironolactone or control, we analysed 421 participants with available LAVi and 276 proteomic measurements (Olink) at baseline, month 1 and 9 (mean age 73 ± 6 years; women 26%; LAVi 32 ± 9 ml/m2). Circulating proteins associated with LAVi were also assessed in asymptomatic individuals from a population‐based cohort (STANISLAS; n = 1640; mean age 49 ± 14 years; women 51%; LAVi 23 ± 7 ml/m2). In both studies, greater LAVi was significantly associated with greater left ventricular masses and volumes. In HOMAGE, after adjustment and correction for multiple testing, greater LAVi was associated with higher concentrations of matrix metallopeptidase‐2 (MMP‐2), insulin‐like growth factor binding protein‐2 (IGFBP‐2) and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) (false discovery rates [FDR] <0.05). These associations were externally replicated in STANISLAS (all FDR <0.05). Among these biomarkers, spironolactone decreased concentrations of MMP‐2 and NT‐proBNP, regardless of baseline LAVi (pinteraction > 0.10). Spironolactone also significantly reduced LAVi, improved left ventricular ejection fraction, lowered E/e', blood pressure and serum procollagen type I C‐terminal propeptide (PICP) concentration, a collagen synthesis marker, regardless of baseline LAVi (pinteraction > 0.10). Conclusion: In individuals without heart failure, LAVi was associated with MMP‐2, IGFBP‐2 and NT‐proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF

Author

Clephas, Pascal R. D., primary, Malgie, Jishnu, additional, Schaap, Jeroen, additional, Koudstaal, Stefan, additional, Emans, Mireille, additional, Linssen, Gerard C. M., additional, de Boer, Grytsje A., additional, van Heerebeek, Loek, additional, Borleffs, C. Jan Willem, additional, Manintveld, Olivier C., additional, van Empel, Vanessa, additional, van Wijk, Sandra, additional, van den Heuvel, Mieke, additional, da Fonseca, Carlos, additional, Damman, Kevin, additional, van Ramshorst, Jan, additional, van Kimmenade, Roland, additional, van de Ven, Arjen R. T., additional, Tio, René A., additional, van Veghel, Dennis, additional, Asselbergs, Folkert W., additional, de Boer, Rudolf A., additional, van der Meer, Peter, additional, Greene, Stephen J., additional, Brunner‐La Rocca, Hans‐Peter, additional, and Brugts, Jasper J., additional

Published
2023
Full Text
View/download PDF

44. Use of loop diuretics in patients with chronic heart failure: an observational overview

Author

Scholte, Niels TB, primary, Aydin, Dilan, additional, Linssen, Gerard CM, additional, Koudstaal, Stefan, additional, Rademaker, Philip C, additional, Geerlings, Peter R, additional, van Gent, Marco WF, additional, Aksoy, Ismail, additional, Oosterom, Liane, additional, Boersma, Eric, additional, Brunner-La Rocca, Hans-Peter, additional, and Brugts, Jasper J, additional

Published
2023
Full Text
View/download PDF

47. Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care

Author

Barrett, Matthew, Boyne, Josiane, Brandts, Julia, Brunner-La Rocca, Hans-Peter, De Maesschalck, Lieven, De Wit, Kurt, Dixon, Lana, Eurlings, Casper, Fitzsimons, Donna, Golubnitschaja, Olga, Hageman, Arjan, Heemskerk, Frank, Hintzen, André, Helms, Thomas M., Hill, Loreena, Hoedemakers, Thom, Marx, Nikolaus, McDonald, Kenneth, Mertens, Marc, Müller-Wieland, Dirk, Palant, Alexander, Piesk, Jens, Pomazanskyi, Andrew, Ramaekers, Jan, Ruff, Peter, Schütt, Katharina, Shekhawat, Yash, Ski, Chantal F., Thompson, David R., Tsirkin, Andrew, van der Mierden, Kay, Watson, Chris, and Zippel-Schultz, Bettina

Published
2019
Full Text
View/download PDF

50. Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: a prospective cross‐over study

Author

Weerts, Jerremy, primary, Amin, Hesam, additional, Barandiarán Aizpurua, Arantxa, additional, Gevaert, Andreas B., additional, Handoko, M. Louis, additional, Dauw, Jeroen, additional, Tun, Han Naung, additional, Rommel, Karl‐Philipp, additional, Verbrugge, Frederik H., additional, Kresoja, Karl‐Patrik, additional, Sanders‐van Wijk, Sandra, additional, Brunner‐La Rocca, Hans‐Peter, additional, Bayés‐Genís, Antoni, additional, Lumens, Joost, additional, Knackstedt, Christian, additional, and van Empel, Vanessa P.M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results